Brown Advisory’s Ocular Therapeutix OCUL Stock Holding History

Brown Advisory’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$884K	Hold	90,000	–	–	﹤0.01%	945
2026 Q1	$762K	Hold	90,000	–	–	﹤0.01%	933
2025 Q4	$1.09M	Hold	90,000	–	–	﹤0.01%	823
2025 Q3	$1.05M	Hold	90,000	–	–	﹤0.01%	821
2025 Q2	$835K	Hold	90,000	–	–	﹤0.01%	852
2025 Q1	$660K	Hold	90,000	–	–	﹤0.01%	903
2024 Q4	$769K	Hold	90,000	–	–	﹤0.01%	881
2024 Q3	$783K	Hold	90,000	–	–	﹤0.01%	849
2024 Q2	$616K	Hold	90,000	–	–	﹤0.01%	896
2024 Q1	$819K	Hold	90,000	–	–	﹤0.01%	827
2023 Q4	$401K	Hold	90,000	–	–	﹤0.01%	982
2023 Q3	$283K	Hold	90,000	–	–	﹤0.01%	1029
2023 Q2	$464K	Hold	90,000	–	–	﹤0.01%	926
2023 Q1	$474K	Hold	90,000	–	–	﹤0.01%	923
2022 Q4	$253K	Hold	90,000	–	–	﹤0.01%	1058
2022 Q3	$373K	Hold	90,000	–	–	﹤0.01%	924
2022 Q2	$362K	Hold	90,000	–	–	﹤0.01%	916
2022 Q1	$445K	Hold	90,000	–	–	﹤0.01%	884
2021 Q4	$627K	Hold	90,000	–	–	﹤0.01%	829
2021 Q3	$900K	Hold	90,000	–	–	﹤0.01%	713
2021 Q2	$1.28M	Hold	90,000	–	–	﹤0.01%	649
2021 Q1	$1.48M	Buy	+90,000	New	+$1.73M	﹤0.01%	636

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory's OCUL Position: Q2 2026 in Review

Brown Advisory held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 90,000 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #945.

Brown Advisory first reported a position in OCUL in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.48M in Q1 2021. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Brown Advisory held 90,000 shares of Ocular Therapeutix worth $884K as of Q2 2026.
Brown Advisory left its Ocular Therapeutix share count unchanged in Q2 2026.
Ocular Therapeutix made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #945 holding.
Brown Advisory first reported a position in Ocular Therapeutix in Q1 2021 and has held it in 22 quarters since.
Brown Advisory's Ocular Therapeutix position peaked at $1.48M in Q1 2021.
263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.